Frontier Biotechnologies(SH:688221) Xin Lang Cai Jing·2025-10-31 03:20Core Viewpoint - Frontier Biopharmaceuticals has experienced a 5.03% increase in stock price, reaching 15.24 CNY per share, with a total market capitalization of 5.709 billion CNY, indicating a strong market performance over the past four days with a cumulative increase of 3.5% [1] Company Overview - Frontier Biopharmaceuticals (Nanjing) Co., Ltd. is located in Jiangning District, Nanjing, Jiangsu Province, and was established on January 15, 2013. The company went public on October 28, 2020 [1] - The company focuses on the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs, with a strong emphasis on HIV long-acting treatment and immunotherapy [1] - Frontier Biopharmaceuticals has one marketed original anti-HIV drug with global patents and two drugs in clinical trials that are patented or licensed [1] - The revenue composition of the company is primarily from the anti-HIV drug Aikening, accounting for 91.29%, while other products contribute 8.71% [1] Shareholder Information - E Fund's Healthcare Industry Mixed A Fund (110023) has entered the top ten circulating shareholders of Frontier Biopharmaceuticals, holding 7.7173 million shares, which is 2.06% of the circulating shares [2] - The fund has realized a floating profit of approximately 5.6336 million CNY today, with a floating profit of 3.7815 million CNY during the four-day increase [2] - E Fund's Healthcare Industry Mixed A Fund was established on January 28, 2011, with a current scale of 3.802 billion CNY and has achieved a year-to-date return of 31.25% [2]